Imaging test using a CD70-targeted tracer for kidney cancer
Tests a PET scan tracer to help identify kidney cancer in adults.
Key facts
- Who runs it
- RenJi Hospital
- Where
- Shanghai, ChinaSee the site
- Trial code
- Registry title
- CD70-targeted immunoPET Imaging of Kidney Cancer
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 300 people, planned
- Started
- 27 Nov 2024
- Expected to end
- Nov 2027
- Type of study
- Interventional
- Treatments tested
- [18F]RCCB6
- Record updated
- 31 December 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with kidney cancer, or suspected kidney cancer on imaging, to test a new PET/CT scan with [18F]RCCB6.
- Age
- 18 to 80 years
- Sex
- Women and men can both join.
- Disease stage
- Kidney cancer confirmed by tissue test, especially clear cell and papillary renal cell carcinoma, or suspected kidney cancer on imaging.
- Earlier treatment
- No serious surgery in the last month.
Main reasons for not taking part
- Pregnancy
- Severe liver or kidney insufficiency
- Serious surgery in the last month
- Allergy to antibody or single-domain antibody radiopharmaceuticals
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Aged 18-80 year-old and of either sex；
- Histologically confirmed diagnosis of kidney cancer (especially clear cell renal cell carcinoma and papillary renal cell carcinoma) or suspected kidney cancer by diagnostic imaging
- Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol
Who cannot take part
- Severe hepatic and renal insufficiency
- History of serious surgery in the last month
- Allergic to antibody or single-domain antibody radiopharmaceuticals
- Pregnancy；
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Where in China
- Renji Hospital, School of Medicine, Shanghai Jiao Tong UniversityShanghai, ChinaContact: Weijun Wei, Ph.D. & M.D.Taking people
About the trial
What the trial wants to find out
The aim of this study is to establish and optimize the [18F]RCCB6 PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agent in renal cancer (especially clear cell renal cell carcinoma) wil be evaluated.
The group in the trial
- CD70-targeted immunoPET imagingTreatment being tested
Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.
Treatment: [18F]RCCB6
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Study of the Clinical Application of [18F]RCCB6 PET/ CT Imaging in the Diagnosis of Kidney Cancer
- Plain-language title
- Imaging test using a CD70-targeted tracer for kidney cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06680089, who can take part
- Publications
- CD70-Targeted [18F]RCCB6 Immuno-PET/CT for Diagnosing Clear Cell Renal Cell Carcinoma Metastases: A Prospective Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026
- Record updated
- 31 December 2025